Inhibitory effect of diacerein on osteoclastic bone destruction and its possible mechanism of action

Yaoxue Xuebao

Volumn 41, Issue 6, 2006, Pages 555-560

  Wang, Lin ^a   Mao, Yu Jia ^a   Wang, Wen Jie ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Diacerein; Osteoclast; Osteoprotegerin; Receptor activator of NF B ligand

Indexed keywords

ANTHRAQUINONE DERIVATIVE; ANTIINFLAMMATORY AGENT; DIACETYLRHEIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

ANIMAL; ARTICLE; BIOSYNTHESIS; BONE MARROW CELL; C57BL MOUSE; CELL LINE; COCULTURE; CYTOLOGY; GENETICS; METABOLISM; MOUSE; NEWBORN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PHYSIOLOGY;

ANIMALS; ANIMALS, NEWBORN; ANTHRAQUINONES; ANTI-INFLAMMATORY AGENTS; BONE MARROW CELLS; BONE RESORPTION; CELL LINE; COCULTURE TECHNIQUES; MICE; MICE, INBRED C57BL; OSTEOBLASTS; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RNA, MESSENGER;

EID: 33746851690     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Stenbeck G, Horton MA. A new specialized cell-matrix interaction in actively resorbing osteoclasts [J]. Cell Sci, 2000,113:1577-1587.
2. Nakamura I, Kadono Y, Takayanagi H, et al. IL-1 regulates cytoskeletal organization in osteoclasts via TNF receptor-associated factor 6/c-Src complex [J]. J Immunol, 2002,168:5103-5109.
3. Jimi E, Nakamura I, Ikebe T, et al. Activation of NF-κB is involved in the survival of osteoclasts promoted by interleukin-1 [J]. Biol Chem, 1998,273:8799-8805.
4. Tamura T, Shirai T, Kosaka N, et al. Pharmacological studies of diacerein in animal models of inflammation. Arthritis and bone resorption [J]. Eur J Pharmacol, 2002,498:81-87.
5. Li TS, Hamano K, Suzuki K. Improved angiogenic potency by implantation of ex vivo hypoxia prestimulated bone marrow cells in rats [J]. Am J Physiol Heart Circ Physiol, 2002,283:H468-473.
6. Lai FP, Cole-Sinclair M, Cheng WJ. Myeloma cells can directly contribute to the pool of RANKL in bone by-passing the classic stromal and osteoblast pathway of osteoclast stimulation [J]. Br J Haematol, 2004,126: 192-201.
7. Lai FP, Cole-Sinclair M, Cheng WJ, et al. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation [J]. Br J Haematol, 2004,126; 192-201.
8. Yu JL, Dou DQ, Chen XH. Ginsenoside-Ro enhances cell proliferation and modulates Th1/Th2 cytokines production in murine splenocytes [J]. Acta Pharm Sin, 2005,40:332-336.
9. Ivashkiv LB. Cytokine expression and cell activation in inflammatory arthritis [J]. Adv Immunol, 1996,156; 3952-3960.
10. Wong BR, Josien R, Lee SY, et al. The TRAF family of signal transducers mediates NF-kappa B activation by the TRANCE receptor [J]. J Biol Chem, 1998,273; 28355-28359.
11. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis [J]. Nature, 1999,397; 315-323.
12. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density [J]. Cell, 1997,89;309-319.